Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells
- 14 September 2007
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 361 (1) , 189-195
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid TumorsClinical Cancer Research, 2007
- Phase II trial of high‐dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen‐independent prostate cancerCancer, 2006
- Prospective Study of Predictors of Vitamin D Status and Cancer Incidence and Mortality in MenJNCI: Journal of the National Cancer Institute, 2006
- Promise of vitamin D analogues in the treatment of hyperproliferative conditionsMolecular Cancer Therapeutics, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- A Prospective Study of Calcium Intake and Incident and Fatal Prostate CancerCancer Epidemiology, Biomarkers & Prevention, 2006
- Low Plasma Adiponectin Levels and Risk of Colorectal Cancer in Men: A Prospective StudyJNCI: Journal of the National Cancer Institute, 2005
- Vitamin D: More Than a “Bone-a-Fide” HormoneMolecular Endocrinology, 2003
- Pharmacokinetics of high-dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxelClinical Pharmacology & Therapeutics, 2002
- Enhancement of 1,25-Dihydroxyvitamin D3-Mediated Antitumor Activity With DexamethasoneJNCI: Journal of the National Cancer Institute, 1998